论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
患有胰腺癌和肾癌的患者单独接受开环异落叶松树脂醇二葡萄糖苷治疗的成功结果:病例报告
Authors Wu H, Zhang XH, Wang LP, Tian HD, Liu GR, Yang DH, Liu SL
Received 23 October 2023
Accepted for publication 6 March 2024
Published 15 March 2024 Volume 2024:17 Pages 167—175
DOI https://doi.org/10.2147/IMCRJ.S446184
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Xudong Zhu
Introduction: Pancreatic cancer (PC) is among the deadliest malignancies. Kidney cancer (KC) is a common malignancy globally. Chemo- or radio-therapies are not very effective to control PC or KC, and overdoses often cause severe site reactions to the patients. As a result, novel treatment strategies with high efficacy but without toxic side effects are urgently desired. Secoisolariciresinol diglucoside (SDG) belongs to plant lignans with potential anticancer activities, but clinical evidence is not available in PC or KC treatment.
Patient Concerns: We report a rare case of an 83-year-old female patient with pancreatic and kidney occupying lesions that lacked the conditions to receive surgery or chemo- or radiotherapy.
Diagnosis: Pancreatic and kidney cancers.
Interventions: We gave dietary SDG to the patient as the only therapeutics.
Outcomes: SDG effectively halted progression of both PC and KC. All clinical manifestations, including bad insomnia, loss of appetite, stomach symptoms, and skin itching over the whole body, all disappeared. The initial massive macroscopic hematuria became microscopic and infrequent, and other laboratory results also gradually returned to normal. Most of the cancer biomarkers, initially high such as CEA, CA199, CA724, CA125, came down rapidly, among which CA199 changed most radically. This patient has had progression-free survival of one year so far.
Conclusion: These results demonstrate the potent inhibitory effects of SDG on PC and KC of this patient and provide promising novel therapeutics for refractory malignant tumors.
Keywords: pancreatic cancer, kidney cancer, lignans, secoisolariciresinol diglucoside, CA199